Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating ...

Singer Manizha Sangin, who criticized the special military operation and expressed sympathy for the terrorists detained after ...

The Adelaide mom is met with sympathy, her husband with praise and both of them cop opinions that belong back in 1963. She’s ...

Both Emanuel Colombini and yours truly had a poster of a Lamborghini Diablo on our respective bedroom walls. However, only one of us made that childhood dream come true: not just by owning a Diablo, ...

There had been a fleeting window of sympathy, and then the story flipped. Israel’s military steps became the headline—its ...

IMM2510, a differentiated PD-L1xVEGF bispecific antibody with upcoming data in H2 2025. Click to read why TIL is a Hold.

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

ICE raids are disrupting worksites across the country, particularly construction sites, as President Trump’s mass deportation ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

Pfizer announces positive results from phase 3 BASIS study of Hympavzi in haemophilia A or B with inhibitors: New York Friday, June 27, 2025, 10:00 Hrs [IST] Pfizer Inc. announced ...